Wednesday, June 10, 2026

pharma · Anal Neoplasm · Lassa Fever · INO

INOVIO Pharmaceuticals

INOVIO Pharmaceuticals clinical programs — 25 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US HQ
203 Employees
Public company Type
INO · NYSE Ticker
Company details
Status
Public
HQ
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA 19462, US
Employees
203
Programs
46
Drugs
8
Patents
75
Intelligence · Clinical Programs

INOVIO Pharmaceuticals projects

25 ClinicalTrials.gov programs sponsored by INOVIO Pharmaceuticals.

INOVIO Pharmaceuticals has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 2mg INO-5150 and electroporation device CELLECTRA®-5P

    INOVIO PHARMACEUTICALS, INC.

    Prostate Cancer

    phase 1 mab completed

    1 trial
  2. Electroporation-Mediated Plasmid DNA Vaccine Therapy

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis

    phase 1 mab active

    1 trial
  3. FVH1 - a DNA-based influenza vaccine

    INOVIO PHARMACEUTICALS, INC.

    Influenza, Human

    phase 1 mab completed

    1 trial
  4. GLS-5700

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    2 trials
  5. GLS-6150

    INOVIO PHARMACEUTICALS, INC.

    HCV Infection

    phase 1 mab completed

    1 trial
  6. INO-1400

    INOVIO PHARMACEUTICALS, INC.

    Breast Cancer

    phase 1 mab completed

    1 trial
  7. INO-1800

    INOVIO PHARMACEUTICALS, INC.

    Hepatitis B

    phase 1 mab completed

    1 trial
  8. INO-3106, INO-9012

    INOVIO PHARMACEUTICALS, INC.

    Aerodigestive Precancerous Lesions and Malignancies

    phase 1 mab completed

    1 trial
  9. INO-3401 + EP

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial
  10. INO-3605

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial
  11. INO-4201

    INOVIO PHARMACEUTICALS, INC.

    Ebola Virus Disease

    phase 1 mab completed

    1 trial
  12. INO-4201

    INOVIO PHARMACEUTICALS, INC.

    Ebola Vaccine

    phase 1 mab completed

    1 trial
  13. INO-4500

    INOVIO PHARMACEUTICALS, INC.

    Lassa Fever

    phase 1 small molecule completed

    2 trials
  14. INO-5401

    INOVIO PHARMACEUTICALS, INC.

    BRCA1/2 Mutation

    phase 1 small molecule active

    1 trial
  15. INO-A002

    INOVIO PHARMACEUTICALS, INC.

    Healthy Volunteers

    phase 1 mab completed

    1 trial
  16. NKTR-214 (Cohort A)

    INOVIO PHARMACEUTICALS, INC.

    Metastatic Castration-resistant Prostate Cancer

    phase 1 small molecule completed

    1 trial
  17. PENNVAX-B

    INOVIO PHARMACEUTICALS, INC.

    HIV-1 Infection

    phase 1 mab completed

    1 trial
  18. V930

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial
  19. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Human Papillomavirus (HPV)

    phase 1 mab completed

    1 trial
  20. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Papillomavirus Infections

    phase 1 mab completed

    1 trial
  21. VGX-3400

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial
  22. VGX-3400X

    INOVIO PHARMACEUTICALS, INC.

    Healthy

    phase 1 mab completed

    1 trial
  23. VGX-6150

    INOVIO PHARMACEUTICALS, INC.

    Hepatitis C, Chronic

    phase 1 mab completed

    1 trial
  24. dMAb AZD5396

    INOVIO PHARMACEUTICALS, INC.

    Healthy Volunteers

    phase 1 other completed

    1 trial
  25. sD-NP-GT8 DNA

    INOVIO PHARMACEUTICALS, INC.

    HIV Infections

    phase 1 mab completed

    1 trial

Frequently asked questions

How many clinical projects does INOVIO Pharmaceuticals have?

25 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.